Questions aim low, answers land high: the dialogue keeps correcting expectations upward with facts already in hand
The model's full reasoning — Q3 2023 call → NOWe need to determine if there is a clear, recurring mismatch in level between questioners' assumptions and management's reports, with the mismatch running upward. The questions should be more modest/cautious/troubled than what management reports, and management should correct upward with concrete already-happening facts. Let's analyze the Q&A exchanges. First question from Anthony Vendetti: asks about FDA denial, what indications are approved in U.S. Management answers with list of approved indications. That's not really a mismatch; it's a factual question. Then follow-up: "Even though the FDA denied De Novo... it is still approved. Can you remind us what indications it is approved for right now?" That's just clarification. Then: "If they deny the appeal, do you wait for the last patient follow-up data and then resubmit then? Or what are the next steps?" Management explains appeal process and potential resubmission. That's not a mismatch; it's a procedural question. Then: "Can you talk about the initial sales traction in Brazil and then how are sales going in China? Yes, in Canada." Management responds with positive developments: orders shipped, KOLs trained, China progress. That's a correction upward? The question asks about traction, management gives positive facts. But is the question premised on a lower picture? Not necessarily; it's just asking for update. Then: "I know you're working with Medtronic there. In Japan, you're working with Terumo... Can you talk a little bit about that?" Management explains Terumo working on regulatory approval, IceCure selling directly. That's neutral. Second questioner Ben Haynor: "what is the FDA looking at as a comparator group?" Management answers. Then Ben says "I mean, I guess to me it seems like kind of an odd comparator... maybe that's more of a rhetorical question than anything." Management responds with belief they can get via appeal. That's not a mismatch. Third questioner Kemp Dolliver: "Is there a basic challenge here that the subpopulation you defined as part of your filing probably hasn't been studied with the same definition in other populations?" Management answers about appeal and new article. That's a question about a challenge, but management doesn't really correct upward; they explain. Then: "How quickly can you re-file...?" Management gives timeline.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| EGP | EastGroup Properties, Inc. | Q4 2023 | 2024-02-08 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| ADM | Archer-Daniels-Midland Company | Q4 2022 | 2023-01-26 | C+ |
| HBAN | Huntington Bancshares Incorporated | Q4 2022 | 2023-01-20 | B |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| ICL | ICL Group Ltd | Q3 2022 | 2022-11-09 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| HLNE | Hamilton Lane Incorporated | Q1 2023 | 2022-08-02 | C+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| PRGS | Progress Software Corporation | Q2 2022 | 2022-06-28 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| BHF | Brighthouse Financial, Inc. | Q1 2022 | 2022-05-10 | C |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| STM | STMicroelectronics NV | Q3 2018 | 2018-10-24 | C+ |
| TMHC | Taylor Morrison Home Corporation | Q2 2018 | 2018-08-01 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| LAUR | Laureate Education, Inc. | Q1 2018 | 2018-05-13 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| KRG | Kite Realty Group Trust | Q1 2018 | 2018-04-26 | C+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| SNA | Snap-on Incorporated | Q3 2017 | 2017-10-19 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DHR | Danaher Corporation | Q1 2017 | 2017-04-20 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| JHX | James Hardie Industries plc | Q3 2016 | 2016-02-19 | B+ |
GOGO · Q1 2016 → YESThe question is about whether there's a clear, recurring mismatch where analysts assume a more modest/cautious/troubled version, and management corrects UPWARD with things already happening. YES The analysts' questions repeatedly frame the business around cautious or risk-oriented assumptions—such as ARPA trajectory concerns amid competition, cash and liquidity needs, potential sentiment issues with the Gogo brand, and competitive pressures from Panasonic—while management consistently corrects upward by citing concrete, already-realized facts: record revenues, 2Ku now in service on AeroMexico and IAG, over 1,000 planes awarded, Delta increases, install records, and backlog progress already achieved. This pattern repeats across multiple exchanges, with management pointing to present-tense operational realities that exceed the cautious premises embedded in the questions.
LAUR · Q1 2018 → YESThe question is about whether there's a clear, recurring mismatch in level between what the questioners assume and what management reports, with the mismatch running UPWARD. Analysts think more modest...YES The transcript shows a clear recurring mismatch running upward. Analysts repeatedly probe cautious angles—Chile as a potential end rather than final ruling, Brazil FIES exposure as a risk, margin phasing and guidance including divestitures, Turkey as needing update, FCF not raised despite Chile, leverage post-St. Augustine, and Accelerator 2.0 health sciences—framing the business around lingering uncertainties or modest upside.
JHX · Q3 2016 → YESThe question is about whether there's a clear, recurring mismatch where analysts assume a more modest/cautious/troubled version, and management corrects UPWARD with concrete things already happening. ...NO The transcript shows analysts probing for signs of weakness or slowdowns (seasonal margins, destocking, Europe performance, PDG pickup, volumes vs targets), but management repeatedly corrects upward with concrete current facts: strong Q3 margins (2.6 points better), no destocking, plants running well, costs controlled, 12% volume growth, Europe already through the one-off, and inventory normalized.